Industries > Pharma > Global Rare Disease Drugs Market Forecast 2019-2029

Global Rare Disease Drugs Market Forecast 2019-2029

Oncology, Metabolic Diseases, Neurologic Diseases, Haematology Diseases, Infectious Diseases, Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies

PUBLISHED: 01 August 2019
PAGES: 250
PRODUCT CODE: PHA0461
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0461 Categories: , Tags: , , ,

The global rare disease drugs market is estimated to reach $257bn in 2024 and is expected to grow at a CAGR of 11.3% throughout the forecast period. In 2018, rare oncology diseases segment held 36% of share in the global rare disease drugs market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 250-page report you will receive 145 charts– all unavailable elsewhere.

The 250-page report provides clear detailed insight into the global rare disease drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Rare Disease Drugs Market forecasts from 2019-2029

• Revenue forecasts for the global rare disease drugs market by application from 2019-2029:
• Rare Oncology Diseases
• Rare Metabolic Diseases
• Rare Neurologic Diseases
• Rare Hematology Diseases
• Rare Infectious Diseases
• Other Rare Diseases

Global Rare Disease Drugs Market Forecast 2019-2029

• Revenue forecasts for the global rare disease drugs market by distribution channel from 2019-2029:
• Specialty Pharmacies
• Hospital Pharmacies
• Retail Pharmacies

• Revenue forecasts for the global rare disease drugs market by drug from 2019-2029:
• Avonex
• Copaxone
• Gleevec
• Imbruvica
• MabThera/Rituxan
• Opdivo
• Rebif
• Revlimid
• Sprycel
• Tasigna
• Velcade
• Other Drugs

• Revenue forecasts for the rare disease drugs market by Regional and National Market from 2019-2029:
• North America (US, Canada)
• Europe (Germany, UK, France, Italy, Spain)
• Asia-Pacific (Japan, China, India, South Korea)
• RoW (Brazil, Mexico, South Africa, Russia)

• Profiles and discussion on the leading companies in the rare disease drugs market:
• AbbVie
• Bristol-Myers Squibb (BMS)
• Celgene
• Merck & Co., Inc.
• Novartis
• Pfizer
• Roche
• Sanofi
• Takeda
• Teva

• Rare disease drugs pipeline analysis covering rare oncology drugs, rare autoimmune disease drugs, blood-related rare disease drugs, rare genetic disease drugs and rare infectious disease drugs.

SWOT Analysis and Porter’s Five Forces analysis of the global rare disease drugs market

• Discussion on factors that drive and restrain the global rare disease drugs market as well as opportunities in this market.

• Key Questions Answered by this Report:
• What are the global revenue prospects for the period 2019 to 2029?
• What are the leading national market potentials from 2019 to 2029?
• How is the rare disease drugs market evolving?
• What is driving and restraining the rare disease drugs market?
• What are the market shares of each segment of the overall rare disease drugs market?
• How will main rare disease drugs submarket segments develop over the forecast period and how much revenue will these submarkets account for in 2029?
• How will the market shares for each rare disease drugs submarket develop from 2018 to 2029?
• Which therapies can succeed and what revenues could they generate to 2029?
• What will be the main commercial drivers for the market from 2018 to 2029?
• How will market shares of prominent national markets change from 2018, and which countries will lead the market in 2029, achieving highest revenues and fastest growth?
• How will that industry evolve between 2018 and 2029, especially in R&D?

Visiongain’s study is intended for anyone requiring commercial analyses for the Global Rare Disease Drugs Market. You find data, trends and predictions.

Buy our report today Global Rare Disease Drugs Market Forecast 2019-2029: Oncology, Metabolic Diseases, Neurologic Diseases, Haematology Diseases, Infectious Diseases, Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Global Rare Disease Drugs Market Forecast 2019-2029


Download sample pages

Complete the form below to download your free sample pages for Global Rare Disease Drugs Market Forecast 2019-2029


Latest Pharma news

Visiongain’s analysis indicates that total revenue on Tuberculosis Treatment Drugs Market will be $1,080 million in 2020 due to the World Health Organization strong commitment towards ending TB leading to increase in funding for the research and development both in developed as well and under-developed markets

Due to maturity of generic drug market, companies are moving away from generics drug into therapeutic market by building strong portfolio for development of anti-tuberculosis drug emphasizing all types of TB cases.

06 April 2020

READ

The Global Wound Care Market Is Set to Boom, Particularly in Emerging Economies

The global wound care market is big, and only set to grow bigger.  Currently, estimates show a CAGR of 4.6% in the years to come, with the overall market growing from US$19.8 billion in 2019 to US$24.8 billion by 2024.  The industry is ripe with opportunity, with that growth coming from several factors – but most especially growth in emerging …

30 March 2020

READ

“The global nasal drug delivery technology market is estimated to have reached $44,385 million in 2019” says new Visiongain report

Nasal Sprays segment held the largest market share of the global nasal drug delivery technology market in 2019.

30 March 2020

READ

“Global Stem Cell Technologies and Applications market set to grow to $10903.0m by 2025” says new Visiongain report

New technologies will be needed to ensure that scaling-up of manufacturing operations can be done effectively once stem cell treatments enter the market.

24 March 2020

READ

Categories

Category